Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Alzheimer's therapy: a BACE in the hand?

    Nature Medicine volume 17, pages 932–933 (2011)Cite this article

    Subjects

    Sam Gandy

    This is a preview of subscription content

    Access options

    Buy article

    Get time limited or full article access on ReadCube.

    $32.00

    Buy

    All prices are NET prices.

    References

    1. Atwal, J.K. et al. A therapeutic antibody targeting BACE1 inhibits amyloid-β production in vivo. Sci. Trans. Med. 3, 84ra43 (2011)

      Article  Google Scholar 

    2. Yu, Y.J. et al. Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target. Sci. Trans. Med. 3, 84ra44 (2011)

      Article  Google Scholar 

    3. Yamakawa, H. et al. β-secretase inhibitor potency is decreased by aberrant beta-cleavage location of the “Swedish mutant” amyloid precursor protein. J. Biol. Chem. 285, 1634–1642 (2010).

      CAS  Article  Google Scholar 

    4. DeMattos, R.B. et al. Peripheral anti-Aβ antibody alters CNS and plasma clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. USA 98, 8850–8855 (2001).

      CAS  Article  Google Scholar 

    5. Vassar, R. et al. β-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 286, 735–741 (1999).

      CAS  Article  Google Scholar 

    6. De Strooper, B., Vassar, R. & Golde, T. The secretases: enzymes with therapeutic potential in Alzheimer disease. Nat. Rev. Neurol. 6, 99–107 (2010).

      CAS  Article  Google Scholar 

    7. Eli, Lilly . Lilly halts development of semagacestat for Alzheimer's disease based on preliminary results of phase 3 clinical trials. <http://newsroom.lilly.com/releasedetail.cfm?releaseid=499794> (2010).

    8. Rinne, J.O. et al. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol. 9, 363–372 (2010).

      CAS  Article  Google Scholar 

    9. Alzheimer Research Forum. Uppsala: Is tau immunotherapy taking off? <http://www.alzforum.org/new/detail.asp?id=2824> (2011).

    10. Kim, S.H. et al. Group II metabotropic glutamate receptor stimulation triggers production and release of Alzheimer's amyloidβ42 from isolated intact nerve terminals. J. Neurosci. 30, 3870–3875 (2010).

      CAS  Article  Google Scholar 

    11. Yoshimizu, T. & Chaki, S. Increased cell proliferation in the adult mouse hippocampus following chronic administration of group II metabotropic glutamate receptor antagonist, MGS0039. Biochem. Biophys. Res. Commun. 315, 493–496 (2004).

      CAS  Article  Google Scholar 

    Download references

    Ethics declarations

    Competing interests

    S.G. is a grantee from Amicus Pharmaceuticals and a data and safety monitoring board member of Pfizer/Johnson&Johnson Alzheimer Immunotherapy Alliance.

    Rights and permissions

    Reprints and Permissions

    About this article

    Cite this article

    Alzheimer's therapy: a BACE in the hand?. Nat Med 17, 932–933 (2011). https://doi.org/10.1038/nm0811-932

    Download citation

    • Published:

    • Issue Date:

    • DOI: https://doi.org/10.1038/nm0811-932

    Further reading

    Search

    Advanced search

    Quick links

    Nature Briefing

    Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

    Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing